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Background: Accurate risk adjustment is crucial for healthcare management and
benchmarking.
Purpose: We aimed to compare the performance of classic comorbidity functions
(Charlson’s and Elixhauser’s), of the All Patients Refined Diagnosis Related Groups (APR-
DRG), and of the Queralt Indices, a family of novel, comprehensive comorbidity indices for
the prediction of key clinical outcomes in hospitalized patients.
Material and Methods: We conducted an observational, retrospective cohort study using
administrative healthcare data from 156,459 hospital discharges in Catalonia (Spain) during
2018. Study outcomes were in-hospital death, long hospital stay, and intensive care unit
(ICU) stay. We evaluated the performance of the following indices: Charlson’s and
Elixhauser’s functions, Queralt’s Index for secondary hospital discharge diagnoses (Queralt
DxS), the overall Queralt’s Index, which includes pre-existing comorbidities, in-hospital
complications, and principal discharge diagnosis (Queralt Dx), and the APR-DRG.
Discriminative ability was evaluated using the area under the curve (AUC), and measures
of goodness of fit were also computed. Subgroup analyses were conducted by principal
discharge diagnosis, by age, and type of admission.
Results: Queralt DxS provided relevant risk adjustment information in a larger number of
patients compared to Charlson’s and Elixhauser’s functions, and outperformed both for the
prediction of the 3 study outcomes. Queralt Dx also outperformed Charlson’s and
Elixhauser’s indices, and yielded superior predictive ability and goodness of fit compared
to APR-DRG (AUC for in-hospital death 0.95 for Queralt Dx, 0.77–0.93 for all other indices;
for ICU stay 0.84 for Queralt Dx, 0.73–0.83 for all other indices). The performance of
Queralt DxS was at least as good as that of the APR-DRG in most principal discharge
diagnosis subgroups.
Conclusion: Our findings suggest that risk adjustment should go beyond pre-existing
comorbidities and include principal discharge diagnoses and in-hospital complications.
Validation of comprehensive risk adjustment tools such as the Queralt indices in other
settings is needed.
Keywords: benchmarking, case-mix, comorbidity, discrimination, multimorbidity, Queralt’s
indices, risk
Introduction
Accurate risk adjustment is crucial in fields such as healthcare management,
benchmarking and research. This has direct implications for the evaluation of health
policies and interventions, the allocation of healthcare resources, and healthcare
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quality.1,2 In the current epidemiological era of non-
communicable chronic diseases becoming pandemic,3
accurate risk adjustment has become particularly challen-
ging, with a large proportion of hospitalized patients being
elderly. Patients now often have multiple concurrent
conditions,4 and frequently develop complications during
a hospital stay.5,6
Comorbidity indices such as Charlson’s7 or Elixhauser’s8
have been widely used as standard methods for risk adjust-
ment in a number of settings.1,9,10 Importantly, although
“comorbidities” and “risk” are often used as synonym
terms, these actually refer to different concepts, the former
being only one of the components of the latter.11 In this
context, comorbidity-only indices such as Charlson’s or
Elixhauser’s may fail to fully capture a patient’s risk, and
more comprehensive tools may be needed.
We have recently developed the Queralt Indices,
a family of risk measurements for hospitalized patients,
which combine and weigh more than 2100 relevant acute
and chronic diagnosis codes, as compared to Charlson’s
index, which includes 17 pre-specified chronic diseases, or
Elixhauser’s, which originally combined 30. The Queralt
Indices allow integrating information from pre-existing
comorbidities, in-hospital complications and principal dis-
charge diagnoses.
The aim of the present study was to compare the perfor-
mance of classic comorbidity-based functions such as
Charlson’s and Elixhauser’s, of a more comprehensive
comorbidity index (Queralt’s Index for secondary hospital
discharge diagnoses, which excludes in-hospital complica-
tions; “Queralt DxS”), of the comprehensive Queralt’s Index
for any hospital discharge diagnoses (which includes pre-
existing comorbidities, in-hospital complications, and prin-
cipal discharge diagnosis; “Queralt Dx”), and of the All
Patients Refined Diagnosis Related Groups (APR-DRG),
which also capture information on medical procedures. We
compared these tools in terms of their ability to predict key
clinical outcomes in hospitalized patients.
Materials and Methods
Setting and Data Source
The present study was conducted in Catalonia (Spain),
a Mediterranean, European region with more than
7 million inhabitants, 81% of whom live in urban munici-
palities. The Catalan Institute of Health (ICS) is the largest
public healthcare provider and serves 75% of those insured
in Catalonia.
For the present analysis we used the ICS population-based,
administrative healthcare database. This database captures
information on medical diagnoses generated in 8 Catalan pub-
lic hospitals. Medical diagnoses are coded in the database
using the International Classification of Diseases, 10th
Revision, Clinical Modification (ICD-10-CM) system.12
Study Design and Study Population
This was an observational, retrospective cohort study. The
unit of analysis was hospital discharge, and we included
all hospital discharges (either home or dead) registered in
the ICS database between January 1st and December 31st,
2018. Only standard hospital stays were included in the
analyses (ie, hospital stays for major ambulatory surgical
interventions and other procedures were excluded).
A same patient could contribute several hospital dis-
charges during the study period.
Computation of the Queralt Indices
Information on medical diagnoses (including preexisting
comorbidities, primary discharge diagnosis, and in-hospital
complications [defined as any non-principal discharge diag-
nosis not present on admission]), was obtained from hospital
discharge reports using definitions based on ICD-10-CM. In
the ICS database, secondary discharge diagnoses not present
on admission are flagged as in-hospital complications, as
compared to secondary discharge diagnoses already present
on admission (i.e., preexisting comorbidities).
The Queralt family of indices currently includes three
simple measures for principal discharge diagnosis (Queralt
DxP), pre-existing comorbidities (Queralt DxS), and in-
hospital complications (Queralt DxC), respectively, and
a comprehensive index combining all of them (Queralt
Dx). Specifically, the development of the Queralt DxS
index was based on a highly computational statistical
algorithm, consisting of two differentiated parts: 1) identi-
fication of significant diagnosis codes groups, and 2)
weighing the effect of each of them. The number of sig-
nificant diagnosis codes groups identified was 2572, of
which 2119 obtained a non-zero weight.
In this report we present the results for the Queralt DxS
and Queralt Dx indices, as likely the currently two most
relevant measures within the Queralt family.
Computation of Other Measures
As comorbidity-only measures, we calculated Charlson’s7
and Elixhauser’s8 indices, using all the information avail-
able on secondary diagnoses coded in the hospital
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discharge reports. Charlson’s index combines and weighs
a pre-specified set of 17 chronic conditions present on
admission,7 while Elixhauser’s uses a set of 30 comorbid-
ities defined as conditions present on admission and unre-
lated to the principal discharge diagnosis. Specifically, we
used Quan’s version of both indices,13 and van Walraven’s
update to calculate the weights in Elixhauser’s measure.14
As case-mix measures, we computed the APR-DRG
Severity level, and the APR-DRG Risk level (version 35).15
Study Outcomes
Three outcomes of interest were defined: in-hospital death,
occurrence of a hospital stay lasting >14 days, and need
for a stay in the intensive care unit (ICU). In-hospital
deaths (from any cause) and stays in the ICU are identified
automatically and recorded exhaustively in the ICS data-
base, for all patients and hospital stays. Length of hospital
stay was calculated (in days) based on the hospital dis-
charge and hospital admission dates, both of which are
recorded systematically in the database. The cut-point of
14 days (as a proxy of a long in-hospital stay) was defined
based on the 90th percentile of the distribution of length of
hospital stays in our area.
Statistical Analyses
The unit of analysis was hospital discharge. Demographic
characteristics and the frequency of recorded conditions
were described using number and proportion (%). We also
described the number and % of hospital discharges in
which each of the three study outcomes were present.
To understand the number of hospitalizations in which
each comorbidity index might provide useful information
for risk adjustment purposes, we calculated and plotted the
proportion of hospitalizations in which no discharge diag-
nosis codes were considered relevant by a given index
according to Charlson’s, Elixhauser’s and Queralt DxS
indices, respectively. Results were presented stratified
by age.
To compare the different measures in terms of their
discriminative ability, we built logistic regression models
for each of the three study outcomes as dependent vari-
ables, using each of the indices as independent variables.
Models were adjusted for age, sex, type of admission
(unplanned, planned), and center, as follows:
● Model 0 (basic model): Age, Sex, Admission Type,
Center
● Model 1: Model 0, Charlson’s
● Model 2: Model 0, Elixhauser’s
● Model 3: Model 0, APR-DRG Severity level
● Model 4: Model 0, APR-DRG Risk level
● Model 5: Model 0, Queralt DxS
● Model 6 (Queralt Dx): Model 0, Queralt DxP,
Queralt DxS, Queralt DxC
For each of these regression models, we computed the
following measures of discrimination and goodness of fit:
the area under the receiver operating characteristic (ROC)
curve (AUC),16 Akaike’s information criterion (AIC),17 the
Bayesian information criterion (BIC),18 and Brier’s score.19
For the ROC analyses, we computed 95% confidence inter-
vals (CIs) using De Long’s method,20 and plotted the ROC
curves of each of the indices for each of the study outcomes.
Subgroup analyses were also conducted, assessing the
performance of these measures specifically in individuals
with a principal discharge diagnosis of selected types of
cancer (colon, pancreatic, lung cancer, leukemias), cardi-
ovascular disease (CVD; acute myocardial infarction, car-
diac arrhythmias, heart failure, acute cerebrovascular
disease), and respiratory conditions (pneumonia, influenza,
acute bronchitis, chronic obstructive pulmonary disease
and bronchiectasis). Conditions were grouped using the
Clinical Classifications Software coding system, which
groups ICD-10 codes.21 Additional subgroup analyses
were conducted among young (0 to 29 years) and older
(≥60 years) patients, as well as by type of admission
(planned, unplanned). Also, a sensitivity analysis exclud-
ing delivery-related hospitalizations was conducted.
In order to prevent overfitting by age, specifically for
APR-DRG we also built regression models excluding age
as covariate, as follows:
● Model 7: Sex + Admission Type + Center + APR-
DRG Severity level
● Model 8: Sex + Admission Type + Center + APR-
DRG Risk level
All analyses were conducted using R software, version
3.5.3.22 R’s statistical package Comorbidity was used for
the calculation of Charlson’s and Elixhauser’s indices.23
Results
Study Population and Characteristics
We included 156,459 hospital discharges occurring
between January 1st and December 31st, 2018 (Table 1).
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The majority of patients were men (51.6%), and most were
60 years of age or older (53.5%). The vast majority of
hospital admissions were unplanned (67.1%), and heart
failure was the most frequent principal discharge diagnosis
(N=5008) among the conditions evaluated.
Study Outcomes
Table 1 also presents the frequency of each of the three
study outcomes. Overall, 4.3% hospitalizations resulted in
an in-hospital death, 7.5% lasted more than 14 days, and
5.3% included an ICU stay. Men had higher in-hospital
mortality than women, their hospital stays were longer,
and needed ICU stays more often. In-hospital mortality
increased with age, with a high of 9.8% for patients 80
years or older; conversely, long hospital stays were more
frequent in newborns. Unplanned stays were associated
with higher in-hospital mortality and with longer stays.
The highest in-hospital mortality was observed in patients
with respiratory failure as their principal diagnosis, fol-
lowed by patients with cerebrovascular disease and
patients with cancer.
Relevant Hospital Discharge Diagnoses
by Comorbidity Index
Figure 1 displays the number of hospitalizations in which no
discharge diagnoses were considered relevant for risk-
adjustment purposes according to Charlson’s, Elixhauser’s
and Queralt DxS indices, respectively. The number of these
hospitalizations was very high using Charlson’s and
Elixhauser’s, especially at young ages. Conversely, this num-
ber was much lower using the Queralt DxS index, particularly
in younger patients, and was almost zero in elderly
individuals.
Prediction of in-Hospital Death
Among comorbidity-only measures, Elixhauser’s index
showed a better performance for the prediction of in-
hospital death, in terms of AUC, than Charlson’s.
Nevertheless, the Queralt DxS index showed the best dis-
criminative ability among the 3 measures (Table 2, and
Figure 2).
When both comorbidity-only and more comprehensive
risk adjustment measures were considered, the Queralt Dx
index was superior to the APR-DRG, and both outper-
formed comorbidity-only measures (Tables 2 and 3, and
Figure 2).
The same trends were true in goodness-of-fit analyses
in terms of AIC (Table S1), BIC (Table S2), and Brier’s
score (Table S3), with the Queralt DxS consistently show-
ing the best performance among comorbidity-based mea-
sures, and the Queralt Dx showing the best goodness-of-fit
for the prediction of in-hospital death when all measures
were considered.
Consistent findings were also observed in AUC sub-
group analyses by discharge diagnosis –patients with
a primary discharge diagnosis of selected types of cancer,
CVD, and respiratory conditions, respectively (Tables 2
Table 1 Number and Characteristics of the Hospital Discharges









All 156,459 4.32 7.48 5.34
Sex
Women 75,674 3.78 6.4 4.07
Men 80,785 4.84 8.5 6.53
Age groups (years)
0 4048 0.91 11.39 20.26
1–4 4659 0.32 3.07 4.53
5−14 4919 0.18 3.56 4.86
15–29 11,010 0.37 4.3 3.32
30–39 14,099 0.61 3.97 2.36
40–49 14,455 1.67 6.68 4.7
50–59 19,575 3.4 8.76 6.66
60–69 25,225 4.52 9.7 6.99
70–79 29,485 5.69 9.11 5.85
80 + 28,984 9.83 7.18 3.16
Hospital admission type
Unplanned 104,939 5.74 8.28 5.5
Planned 51,519 1.44 5.86 5.01
Selected principal
discharge diagnoses
Colon cancer 1027 7.5 12.17 4.97
Pancreatic cancer 553 15.37 19.89 4.16
Lung cancer 1377 17.79 12.71 8.28
Leukemia 448 16.96 50.89 6.25
Acute myocardial
infarction
3020 7.19 9.9 31.29
Arrhythmia 2522 1.19 3.01 4.16
Heart failure 5008 7.85 9.94 2.9
Cerebrovascular
disease
3402 18.34 10.88 14.14
Pneumonia 3138 7.93 8 5
Influenza 1180 5.68 6.86 5.25
Acute bronchitis 3138 1.91 2.64 2.17
COPD 3401 4.76 7.23 1.97
Respiratory failure 768 25.78 12.37 14.58
Abbreviations: COPD, chronic obstructive pulmonary disease; N, number.
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and 3). Nevertheless, 95% CIs were wider than in the
overall analysis.
Prediction of Length of Hospital Stay >14
Days
As for in-hospital death, in AUC analyses for the predic-
tion of long hospital stay Elixhauser’s index showed
a better performance than Charlson’s. Nonetheless, the
Queralt DxS index showed the best discriminative ability
among the three comorbidity-only measures (Table 4, and
Figure 3).
When both comorbidity-only and more comprehensive
risk adjustment tools were considered, the Queralt Dx
index showed once again the best discriminative ability,
with both Queralt Dx and APR-DRG outperforming that
of comorbidity-only measures (Tables 4 and 5, and
Figure 1 Proportion of hospital discharges with no relevant diagnoses for risk-adjustment purposes according to each comorbidity index, stratified by age.
Table 2 In-Hospital Death: AUC Analysis for Comorbidity-Only Measures
Principal Discharge Diagnosis Basic Model Charlson Elixhauser Queralt DxS
AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
All 0.770 0.766 0.775 0.800 0.796 0.805 0.834 0.830 0.838 0.905 0.902 0.908
Colon cancer 0.812 0.770 0.854 0.858 0.820 0.896 0.891 0.859 0.923 0.908 0.880 0.937
Pancreatic cancer 0.708 0.651 0.764 0.799 0.752 0.846 0.824 0.781 0.867 0.908 0.875 0.940
Lung cancer 0.750 0.719 0.781 0.783 0.756 0.811 0.796 0.769 0.823 0.861 0.838 0.884
Leukemia 0.752 0.696 0.808 0.749 0.693 0.806 0.755 0.699 0.812 0.872 0.830 0.913
AMI 0.704 0.670 0.737 0.721 0.689 0.754 0.818 0.792 0.844 0.874 0.851 0.897
Arrhythmia 0.797 0.730 0.863 0.814 0.752 0.875 0.813 0.748 0.877 0.908 0.857 0.959
HF 0.660 0.635 0.686 0.673 0.647 0.698 0.718 0.693 0.744 0.805 0.782 0.828
CeVD 0.643 0.619 0.667 0.670 0.646 0.693 0.692 0.669 0.715 0.821 0.802 0.840
Pneumonia 0.706 0.678 0.735 0.728 0.700 0.756 0.765 0.737 0.792 0.831 0.807 0.855
Influenza 0.781 0.734 0.828 0.791 0.743 0.839 0.837 0.792 0.882 0.873 0.834 0.913
Acute bronchitis 0.857 0.822 0.892 0.845 0.808 0.882 0.856 0.822 0.889 0.896 0.870 0.923
COPD 0.649 0.609 0.689 0.674 0.635 0.713 0.738 0.701 0.775 0.796 0.759 0.833
Resp. failure 0.678 0.637 0.719 0.729 0.689 0.769 0.752 0.713 0.792 0.787 0.750 0.824
Notes: Results presented as AUC and 95% confidence intervals. All models adjusted for age, sex, type of admission, and center. “Queralt Dx” includes principal diagnosis,
pre-existing comorbidities, and in-hospital complications; “Queralt DxS” includes pre-existing comorbidities.
Abbreviations: AMI, acute myocardial infarction; AUC, area under the curve; CeVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; HF, heart failure.
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Figure 3). The same was true in terms of goodness-of-fit
analyses, including AIC (Table S4), BIC (Table S5) and
Brier’s score (Table S6) calculations.
Similar trends were observed in AUC analyses by
principal discharge diagnosis (Tables 4 and 5), although
95% CIs were once again wider than in the overall analy-
sis. The only exception to this was observed in the sub-
group of patients with a principal discharge diagnosis of
leukemia, in which Charlson’s and Elixhauser’s indices
showed a better performance than the Queralt DxS.
Nonetheless, in these patients Queralt Dx also showed
the best performance.
Prediction of ICU Stay
As for the other study outcomes, in AUC analyses the Queralt
DxS showed once again a better discriminative ability for the
prediction of ICU stay than Charlson’s and Elixhauser’s
indices (Table 6), and the Queralt Dx showed the best perfor-
mance across all measures (Tables 6 and 7, and Figure 4). The
same was true in AIC (Table S7), BIC (Table S8) and Brier’s
score (Table S9) goodness-of-fit analyses.
Similar trends were observed in AUC analyses by prin-
cipal discharge diagnosis (Tables 6 and 7). The exceptions to
this were observed in the subgroups of patients with
a principal discharge diagnosis of lung cancer and acute
myocardial infarction, in which the performance of Queralt
DxS was similar to that of the basic model. Nevertheless, in
these patients Queralt Dx improved the performance of
Charlson’s and Elixhauser’s indices, and had a similar pre-
dictive ability as models using APR-DRG.
Consistent results were also observed in subgroup ana-
lyses by age and by type of hospitalization, as well as in
a sensitivity analysis excluding delivery-related hospitali-
zations (Table S10).
Figure 2 ROC curves for the prediction of in-hospital death, all hospital discharges. Queralt Dx includes principal diagnosis, pre-existing comorbidities, and in-hospital
complications; Queralt DxS includes pre-existing comorbidities.
Abbreviations: APR-DRG, All Patients Refined Diagnosis Related Groups; ICU, intensive care unit; ROC, receiver operating characteristic.
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Discussion
In a population-based analysis including 156,459 hospital
discharges from the general population of Catalonia occur-
ring during 2018, a comprehensive comorbidity index (the
Queralt DxS) provided relevant risk adjustment informa-
tion in a larger number of patients compared to the more
parsimonious Charlson’s and Elixhauser’s functions, in all
age groups. Consistent with this, the Queralt DxS index
outperformed the former for the prediction of in-hospital
death, long in-hospital stay, and need for ICU stay in
hospitalized patients. In addition, incorporation of infor-
mation on principal discharge diagnoses and in-hospital
complications (the Queralt Dx index) outperformed
Charlson’s and Elixhauser’s indices even further, and









AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
All 0.910 0.907 0.913 0.928 0.926 0.931 0.888 0.884 0.892 0.923 0.920 0.926 0.949 0.946 0.951
Colon cancer 0.901 0.871 0.931 0.938 0.913 0.963 0.900 0.870 0.929 0.936 0.912 0.959 0.948 0.930 0.966
Pancreatic cancer 0.857 0.811 0.903 0.897 0.862 0.932 0.854 0.809 0.899 0.898 0.864 0.932 0.932 0.906 0.958
Lung cancer 0.828 0.804 0.853 0.866 0.844 0.888 0.823 0.798 0.848 0.857 0.835 0.880 0.892 0.873 0.911
Leukemia 0.841 0.797 0.885 0.867 0.823 0.910 0.776 0.718 0.833 0.844 0.794 0.894 0.911 0.881 0.942
AMI 0.936 0.924 0.949 0.934 0.920 0.948 0.921 0.904 0.938 0.928 0.913 0.943 0.948 0.936 0.961
Arrhythmia 0.957 0.930 0.984 0.958 0.931 0.986 0.957 0.931 0.983 0.962 0.940 0.984 0.965 0.944 0.986
HF 0.837 0.817 0.857 0.865 0.847 0.883 0.807 0.786 0.829 0.855 0.837 0.874 0.865 0.847 0.884
CeVD 0.887 0.872 0.901 0.914 0.901 0.927 0.868 0.852 0.884 0.907 0.893 0.921 0.928 0.917 0.939
Pneumonia 0.861 0.840 0.882 0.872 0.852 0.891 0.818 0.794 0.842 0.858 0.837 0.880 0.880 0.859 0.901
Influenza 0.896 0.864 0.928 0.896 0.864 0.928 0.831 0.784 0.878 0.878 0.838 0.918 0.895 0.858 0.931
Acute bronchitis 0.901 0.877 0.926 0.921 0.901 0.942 0.766 0.712 0.820 0.894 0.860 0.927 0.903 0.876 0.929
COPD 0.799 0.765 0.833 0.819 0.787 0.850 0.752 0.712 0.791 0.798 0.764 0.832 0.850 0.819 0.880
Resp. failure 0.745 0.706 0.784 0.795 0.760 0.830 0.679 0.635 0.724 0.774 0.738 0.811 0.850 0.819 0.881
Notes: *Age not included as covariate in these regression models in order to prevent overfitting. Results presented as AUC and 95% confidence intervals. All models
adjusted for sex, type of admission, center, and age unless stated otherwise. “Queralt Dx” includes principal diagnosis, pre-existing comorbidities, and in-hospital
complications.
Abbreviations: AMI, acute myocardial infarction; APR-DRG, All Patients Refined Diagnosis Related Groups; AUC, area under the curve; CeVD, cerebrovascular disease;
COPD, chronic obstructive pulmonary disease; HF, heart failure.
Table 4 Length of In-Hospital Stay >14 Days: AUC Analysis for Comorbidity-Only Measures
Principal Discharge Diagnosis Basic Model Charlson Elixhauser Queralt DxS
AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
All 0.652 0.647 0.657 0.659 0.655 0.664 0.679 0.675 0.684 0.739 0.734 0.743
Colon cancer 0.657 0.610 0.705 0.660 0.612 0.708 0.675 0.627 0.722 0.687 0.640 0.733
Pancreatic cancer 0.657 0.602 0.712 0.668 0.616 0.720 0.659 0.605 0.714 0.674 0.623 0.726
Lung cancer 0.723 0.686 0.761 0.729 0.691 0.766 0.729 0.692 0.766 0.735 0.699 0.771
Leukemia 0.749 0.704 0.794 0.764 0.719 0.808 0.765 0.720 0.809 0.749 0.704 0.794
AMI 0.711 0.684 0.739 0.734 0.707 0.760 0.764 0.738 0.790 0.792 0.767 0.818
Arrhythmia 0.813 0.768 0.857 0.815 0.768 0.861 0.832 0.790 0.874 0.871 0.835 0.907
HF 0.663 0.639 0.686 0.669 0.645 0.692 0.695 0.673 0.718 0.725 0.703 0.746
CeVD 0.716 0.689 0.743 0.719 0.692 0.745 0.728 0.702 0.755 0.742 0.716 0.768
Pneumonia 0.646 0.612 0.680 0.654 0.621 0.688 0.685 0.651 0.718 0.775 0.747 0.804
Influenza 0.710 0.658 0.762 0.742 0.694 0.791 0.718 0.666 0.771 0.808 0.763 0.853
Acute bronchitis 0.749 0.701 0.796 0.742 0.693 0.791 0.756 0.707 0.805 0.840 0.802 0.879
COPD 0.624 0.586 0.663 0.637 0.599 0.674 0.695 0.659 0.731 0.745 0.713 0.777
Resp. failure 0.642 0.584 0.701 0.641 0.583 0.699 0.651 0.595 0.707 0.679 0.624 0.735
Notes: Results presented as AUC and 95% confidence intervals. All models adjusted for age, sex, type of admission, and center. “Queralt Dx” includes principal diagnosis,
pre-existing comorbidities, and in-hospital complications; “Queralt DxS” includes pre-existing comorbidities.
Abbreviations: AMI, acute myocardial infarction; AUC, area under the curve; CeVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; HF, heart failure.
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yielded superior overall predictive ability compared to the
APR-DRG. The results of several subgroup and sensitivity
analyses were consistent with the overall study findings,
highlighting the applicability of the Queralt Indices to
different patient subgroups and types of hospitalization.
The present findings have important implications for
improving current risk-adjustment paradigms.
Of note, the Queralt Indices are intended to be
a comprehensive family of indices to be used for risk
adjustment purposes, rather than for accurate prediction
of specific outcomes. For this reason, while it would have
been appropiate to exclude, for example, planned hospita-
lizations when developing a model intended to predict the
risk of in-hospital death among urgent hospitalizations,
because our aim was to develop and evaluate a risk adjust-
ment measure, we included all types of hospitalization.
Consistent with this aim, the models adjusting for each
of these risk adjustment tools were compared in terms of
their discrimination ability (AUC), rather than their calli-
bration. In the models, key potential confounders (age and
type of hospitalization) were adjusted for. Also, to address
concerns for potential bias resulting from the inclusion of
delivery-related hospitalizations, a sensitivity analysis
excluding these was conducted. The results were consis-
tent with those of the main analysis.
In our study, Elixhauser’s outperformed Charlson’s
index for the prediction of the 3 study outcomes. This is
consistent with prior studies,24,25 and is likely the conse-
quence of the former being a more comprehensive mea-
sure of chronic comorbidities than the latter. Our results
would support prioritizing Elixhauser’s over Charlson’s
index for risk adjustment purposes.
The Queralt DxS index provided relevant risk adjust-
ment information in a much larger number of patients than
Figure 3 ROC curves for the prediction of length of stay >14 days, all hospital discharges. Queralt Dx includes principal diagnosis, pre-existing comorbidities, and in-hospital
complications; Queralt DxS includes pre-existing comorbidities.
Abbreviations: APR-DRG, All Patients Refined Diagnosis Related Groups; ICU, intensive care unit; ROC, receiver operating characteristic.
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Charlson’s and Elixhauser’s indices. This was particularly
true in younger patients, and is likely explained by the
larger number of diagnoses considered relevant by Queralt
functions – more than 2100, including both acute and
chronic processes – compared to the other indices, which
combine very few, exclusively chronic conditions. This
likely limits their ability to fully capture a patient’s comor-
bidity burden. Moreover, the Queralt DxS showed
improved predictive ability compared to Charlson’s and
Elixhauser’s, which have been two of the gold-standards
of comorbidity-based risk adjustment for years.26,27
Therefore, the Queralt DxS index may allow for a more









AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
All 0.786 0.782 0.790 0.745 0.740 0.750 0.776 0.772 0.781 0.730 0.726 0.735 0.811 0.806 0.815
Colon cancer 0.805 0.765 0.845 0.739 0.694 0.783 0.798 0.758 0.837 0.734 0.690 0.778 0.846 0.813 0.878
Pancreatic cancer 0.714 0.661 0.767 0.685 0.631 0.739 0.705 0.652 0.759 0.682 0.627 0.736 0.707 0.655 0.759
Lung cancer 0.776 0.743 0.808 0.752 0.718 0.787 0.775 0.742 0.807 0.749 0.714 0.783 0.777 0.745 0.810
Leukemia 0.841 0.804 0.878 0.783 0.741 0.826 0.781 0.738 0.824 0.686 0.636 0.735 0.875 0.842 0.907
AMI 0.838 0.816 0.860 0.827 0.805 0.849 0.825 0.803 0.848 0.812 0.789 0.835 0.848 0.827 0.868
Arrhythmia 0.883 0.851 0.914 0.892 0.864 0.920 0.869 0.836 0.903 0.873 0.840 0.906 0.915 0.886 0.944
HF 0.772 0.751 0.793 0.737 0.715 0.760 0.759 0.738 0.780 0.722 0.699 0.744 0.795 0.775 0.816
CeVD 0.777 0.752 0.802 0.757 0.730 0.784 0.740 0.716 0.765 0.709 0.683 0.735 0.790 0.766 0.815
Pneumonia 0.806 0.778 0.834 0.769 0.741 0.798 0.787 0.757 0.817 0.756 0.725 0.787 0.819 0.793 0.845
Influenza 0.844 0.804 0.883 0.815 0.774 0.856 0.798 0.749 0.847 0.769 0.719 0.819 0.860 0.823 0.896
Acute bronchitis 0.829 0.788 0.869 0.807 0.764 0.851 0.770 0.724 0.816 0.766 0.717 0.816 0.862 0.827 0.898
COPD 0.747 0.713 0.780 0.727 0.693 0.760 0.746 0.712 0.779 0.720 0.687 0.754 0.804 0.774 0.834
Resp. failure 0.730 0.676 0.783 0.694 0.638 0.750 0.720 0.666 0.773 0.658 0.602 0.715 0.728 0.677 0.780
Notes: *Age not included as covariate in these regression models in order to prevent overfitting. Results presented as AUC and 95% confidence intervals. All models
adjusted for sex, type of admission, center, and age unless stated otherwise. “Queralt Dx” includes principal diagnosis, pre-existing comorbidities, and in-hospital
complications.
Abbreviations: AMI, acute myocardial infarction; APR-DRG, All Patients Refined Diagnosis Related Groups; AUC, area under the curve; CeVD, cerebrovascular disease;
COPD, chronic obstructive pulmonary disease; HF, heart failure.
Table 6 ICU Stay: AUC Analysis for Comorbidity-Only Measures
Principal Discharge Diagnosis Basic Model Charlson Elixhauser Queralt DxS
AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
All 0.725 0.719 0.730 0.727 0.721 0.733 0.740 0.735 0.746 0.787 0.782 0.792
Colon cancer 0.863 0.813 0.912 0.870 0.823 0.917 0.868 0.818 0.918 0.868 0.813 0.924
Pancreatic cancer 0.940 0.897 0.983 0.928 0.868 0.989 0.930 0.874 0.986 0.935 0.881 0.989
Lung cancer 0.888 0.850 0.926 0.889 0.852 0.927 0.891 0.852 0.929 0.888 0.850 0.926
Leukemia 0.844 0.785 0.903 0.858 0.803 0.912 0.867 0.814 0.921 0.906 0.857 0.954
AMI 0.917 0.906 0.928 0.917 0.906 0.928 0.917 0.907 0.928 0.917 0.906 0.928
Arrhythmia 0.849 0.817 0.882 0.871 0.842 0.899 0.875 0.849 0.901 0.895 0.870 0.920
HF 0.808 0.773 0.842 0.808 0.774 0.843 0.810 0.776 0.845 0.838 0.805 0.871
CeVD 0.783 0.760 0.805 0.784 0.762 0.807 0.786 0.764 0.808 0.824 0.805 0.842
Pneumonia 0.736 0.701 0.771 0.735 0.699 0.770 0.784 0.750 0.818 0.862 0.832 0.892
Influenza 0.826 0.786 0.866 0.825 0.784 0.866 0.831 0.790 0.873 0.913 0.880 0.945
Acute bronchitis 0.885 0.848 0.922 0.888 0.850 0.926 0.910 0.882 0.939 0.922 0.889 0.954
COPD 0.790 0.744 0.837 0.794 0.748 0.839 0.815 0.771 0.860 0.858 0.820 0.897
Resp. failure 0.774 0.730 0.819 0.789 0.746 0.832 0.785 0.740 0.829 0.816 0.772 0.859
Notes: Results presented as AUC and 95% confidence intervals. All models adjusted for age, sex, type of admission, and center. “Queralt Dx” includes principal diagnosis,
pre-existing comorbidities, and in-hospital complications; “Queralt DxS” includes pre-existing comorbidities.
Abbreviations: AMI, acute myocardial infarction; AUC, area under the curve; CeVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; HF, heart
failure; ICU, intensive care unit.
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granular comorbidity-based risk adjustment, even within
relevant disease groups. This may be relevant for example
in patients with heart failure, who may be very heteroge-
neous in terms of their risk of events.28
In addition, we also observed that inclusion, as part of
the risk adjustment strategy, of information on principal
discharge diagnoses and on in-hospital complications (the
Queralt Dx index) improved discriminative ability and
goodness-of-fit even further. This yielded results that out-
performed those from the Queralt DxS, and were superior
to those from gold-standard case-mix measures such as the
APR-DRG. These findings provide support to the notion
that risk adjustment should not only consider pre-existing
comorbidities, but go beyond those, and incorporate these
other features, which also impact a patient’s risk of events.11
The present findings have important implications for
current risk adjustment paradigms. In fields in which such
adjustment is done retrospectively (e.g., benchmarking),
comprehensive comorbidity indices and even more compre-
hensive tools capturing the whole in-hospital clinical pro-
cess (i.e., also including principal discharge diagnosis and
in-hospital complications) provide an invaluable opportu-
nity to improve current standards beyond strategies based
on parsimonious, comorbidity-only indices. In the era of
electronic medical records and of widespread use of auto-
mated disease coding systems in hospital discharge reports,
comprehensive risk adjustment measures such as Queralt’s
can be computed easily and automatically, using readily
available information. This has the potential to inform
healthcare managers and researchers more accurately.
In terms of clinical risk prediction, because the Queralt
Dx index uses information generated during the hospitali-
zation, it would be expected to have limited utility for risk
assessment on admission. Nonetheless, and although this
is not the main purpose of these tools, the Queralt DxS
index, which is solely based on pre-existing comorbidities,
appears as a potentially valuable tool to identify patients at
higher odds of dying, having a long in-hospital stay, or
needing an ICU stay during the index hospitalization;
more accurately than with traditional tools such as
Charlson’s or Elixhauser’s indices. Moreover, it is possible
that risk estimations based on comprehensive information
generated during preceding hospitalizations (e.g., the
Queralt Dx index) could have a value in clinical risk
prediction in subsequent in-hospital stays. Nonetheless,
further studies are needed to test this hypothesis.
Study Limitations
Some limitations are worth discussing. First, we used an
administrative healthcare database to develop the Queralt
indices, as well as to conduct the present comparative
analysis. Administrative databases are known to have









AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
All 0.827 0.823 0.832 0.823 0.819 0.828 0.801 0.796 0.806 0.782 0.776 0.787 0.843 0.839 0.847
Colon cancer 0.903 0.862 0.944 0.906 0.866 0.946 0.897 0.854 0.939 0.899 0.856 0.942 0.911 0.876 0.947
Pancreatic cancer 0.969 0.942 0.997 0.966 0.935 0.996 0.943 0.891 0.994 0.947 0.899 0.996 0.955 0.914 0.996
Lung cancer 0.916 0.883 0.949 0.909 0.873 0.945 0.912 0.878 0.945 0.902 0.865 0.939 0.913 0.880 0.947
Leukemia 0.931 0.890 0.971 0.941 0.906 0.975 0.882 0.815 0.949 0.865 0.791 0.939 0.951 0.919 0.983
AMI 0.923 0.913 0.933 0.923 0.913 0.934 0.922 0.911 0.932 0.922 0.912 0.932 0.927 0.918 0.937
Arrhythmia 0.917 0.896 0.937 0.932 0.914 0.950 0.906 0.880 0.932 0.915 0.890 0.941 0.933 0.915 0.951
HF 0.893 0.869 0.917 0.887 0.860 0.914 0.855 0.826 0.883 0.836 0.807 0.866 0.905 0.881 0.929
CeVD 0.869 0.852 0.885 0.874 0.858 0.891 0.836 0.818 0.853 0.836 0.818 0.854 0.894 0.879 0.909
Pneumonia 0.926 0.906 0.945 0.909 0.887 0.931 0.890 0.866 0.914 0.858 0.829 0.887 0.926 0.905 0.947
Influenza 0.932 0.902 0.961 0.919 0.886 0.951 0.883 0.837 0.928 0.860 0.816 0.905 0.947 0.924 0.969
Acute bronchitis 0.909 0.880 0.938 0.911 0.882 0.940 0.839 0.802 0.877 0.836 0.798 0.874 0.927 0.895 0.958
COPD 0.895 0.853 0.938 0.901 0.870 0.931 0.881 0.834 0.929 0.876 0.842 0.910 0.932 0.902 0.963
Resp. failure 0.898 0.868 0.928 0.857 0.818 0.895 0.869 0.833 0.905 0.774 0.725 0.823 0.863 0.825 0.900
Notes: *Age not included as covariate in these regression models in order to prevent overfitting. Results presented as AUC and 95% confidence intervals. All models
adjusted for sex, type of admission, center, and age unless stated otherwise. “Queralt Dx” includes principal diagnosis, pre-existing comorbidities, and in-hospital
complications.
Abbreviations: AMI, acute myocardial infarction; APR-DRG, All Patients Refined Diagnosis Related Groups; AUC, area under the curve; CeVD, cerebrovascular disease;
COPD, chronic obstructive pulmonary disease; HF, heart failure; ICU, intensive care unit.
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intrinsic limitations when used for research purposes,
including the potential for under-recording of medical
conditions, or the limited validity of some diagnosis
codes, among others.29,30 Nonetheless, in the last decade
the quality of this kind of data has improved markedly,
including in Catalonia, where the ICS database is consid-
ered a high quality research tool.4,31,32
Second, external validation analyses testing the perfor-
mance of the Queralt indices in other populations and
settings are needed to better understand its potential gen-
eralizability. Importantly, although Queralt’s indices have
been developed using data from 8 large public hospitals of
Catalonia, they are flexible, i.e., adaptable to other geo-
graphical settings, through the identification and weighing
of conditions strongly associated with key outcomes (in-
hospital death, length of stay, need for ICU stay, healthcare
cost, or other outcomes) within a given setting. The
software is available online for research purposes, at no
cost.33 Importantly, the Queralt Dx index may perform
better in databases such as ICS’s in which pre-existing
comorbidities and complications developed during the
hospital stay can be differentiated.
Third, in Elixhauser’s index secondary diagnoses
related to the principal diagnosis are typically not consid-
ered by the score. However, in our analysis we allowed
these to be included. This may have overestimated the
discriminative ability of Elixhauser’s index, yielding
a conservative bias when comparing the performance of
the Queralt indices specifically to Elixhauser’s.
Finally, the definition of long hospital stay (as >14
days), although based on the general distribution of dura-
tion of hospital stays in our area, may not be completely
meaningful in specific subgroups of patients, particularly
those with acute, short-duration processes.
Figure 4 ROC curves for the prediction of ICU stay, all hospital discharges. Queralt Dx includes principal diagnosis, pre-existing comorbidities, and in-hospital
complications; Queralt DxS includes pre-existing comorbidities.
Abbreviations: APR-DRG, All Patients Refined Diagnosis Related Groups; ICU, intensive care unit; ROC, receiver operating characteristic.
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Conclusions
Exhaustive comorbidity indices including multiple acute
and chronic conditions may have a better performance for
risk assessment than often used tools such as Charlson’s
and Elixhauser’s. Moreover, our analyses suggest that
risk adjustment should go beyond pre-existing comorbid-
ities and include information on principal discharge diag-
noses and in-hospital complications. In the era of
electronic medical records and of widespread use of
automated disease coding systems in hospitalized
patients, our findings have important implications for
current risk adjustment paradigms, for which exhaustive,
comprehensive, automated tools such as the Queralt
indices may provide an invaluable, inexpensive opportu-
nity to improve risk adjustment. Validation of these tools
in other settings is needed to better understand their
generalizability.
Abbreviations
AIC, Akaike’s information criterion; APR-DRG, All Patients
Refined Diagnosis Related Groups; AUC, area under the
receiver-operator characteristic curve; BIC,Bayesian informa-
tion criterion; CCS, Clinical Classifications Software; CI,
confidence interval; CVD, cardiovascular disease; DRG,
Diagnosis Related Groups; ICD-10-CM, International
Classification of Diseases, 10th Revision, Clinical
Modification; ICS, Catalan Institute of Health (Institut Catala
de Salut); ICU, intensive care unit; Queralt DxS, Queralt’s
Index for secondary hospital discharge diagnoses, excluding
in-hospital, complications; Queralt Dx, Queralt’s Index for
secondary hospital discharge diagnoses, including in-hospital
complications; ROC, receiver operating characteristic.
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